Novel 5-HT2A/mGluR5 blocker for opioid use disorder

Who could benefit from this research

What this research studies

This project tests VVZ-2417, a selective 5-HT2A and mGluR5 antagonist, as an addition to current opioid use disorder treatments. Building on preclinical and early human data, researchers aim to see if the compound can reduce drug-seeking behavior, improve mood-related symptoms, and lower relapse risk. The work includes phased safety assessments in humans and progresses toward evaluating effectiveness in reducing opioid use and withdrawal-related challenges. The initiative is a collaboration between Vivozon Inc. and Virginia Commonwealth University and is supported by NIH funding to advance potential new therapies for OUD.

Why it matters

Where this research is happening

• Virginia Commonwealth University
  Richmond, United States Active

Researchers

• Principal investigator: Moeller, Frederick Gerard — Virginia Commonwealth University
• Study coordinator: Moeller, Frederick Gerard

Related research

Other NIH-funded projects on the same topics.

• Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)

  A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.

  NIH research University of Washington · Seattle, United States · NIH-11599161

• Precise epigenetic drugs for opioid addiction

  A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.

  NIH research Boston Interactome, INC. · Boston, United States · NIH-11578588

• Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans

  This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.

  NIH research Open Aid Alliance · Missoula, United States · NIH-11578581

• Optimizing long-acting PrEP and opioid treatment for people in jails and prisons

  This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.

  NIH research Duke University · Durham, United States · NIH-11565766

• Scaling up medications for opioid use disorder in residential treatment programs

  This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11535207

• Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN

  This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.

  NIH research Native American Community Clinic · Minneapolis, United States · NIH-11533803

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.